UK Markets close in 6 hrs 39 mins

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
210.10-2.20 (-1.04%)
As of 10:50AM CEST. Market open.
Full screen
Previous close212.30
Open219.00
Bid209.70 x 0
Ask210.20 x 0
Day's range209.80 - 214.90
52-week range139.55 - 245.40
Volume64,612
Avg. volume607,463
Market cap62.01B
Beta (5Y monthly)0.45
PE ratio (TTM)21.25
EPS (TTM)9.89
Earnings date02 May 2022 - 06 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est250.50
  • Zacks

    Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top

    Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.

  • Reuters

    Drugmaker Sobi books profit fall on restructuring, Russia

    Swedish Orphan Biovitrum (Sobi) on Thursday reported a smaller-than-expected first-quarter operating profit and said sales grew in emerging markets for its drug Kineret for the treatment of COVID-19. The rare disease drugmaker's operating profit fell to 776 million crowns ($78.6 million) from 1.03 billion and missed the 1.16 billion expected by analysts polled by Refinitiv. The group, which sells drugs targeted at haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, booked restructuring costs of 507 million and a 157 million provision for expected credit losses in Russia.

  • Zacks

    Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates

    Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.